Back to decision-making tree
Print
last updated on 09/02/2026
Biotherapies
Dupilumab: in adult patients and children from 6 months of age
Dupilumab is a human IgG4 monoclonal antibody that binds to the α-subunit of the IL-4 receptor, which is part of the IL-4 and IL-13 receptor complex.
In France, it has Marketing Authorization (MA) and reimbursement for the treatment of moderate-to-severe AD in adults and children from 6 months of age (it is also indicated for moderate-to-severe asthma, eosinophilic esophagitis, and chronic rhino-sinusitis with nasal polyps, thus covering several type 2 inflammatory diseases).
In adults:
Recommended dose:
- 300 mg every 2 weeks after a loading dose of 600 mg at treatment initiation.
Treatment is generally well-tolerated, but a certain number of patients develop conjunctivitis (approximately 20% of patients in real-world studies), most of which are mild to moderate in intensity.
Management, in collaboration with ophthalmologists, using tear substitutes and then topical anti-inflammatories if necessary is required, without the need to interrupt dupilumab treatment.
No additional laboratory tests are required for the initiation or monitoring of the treatment.
Concomitant use of emollients, TCS, TCIs, and phototherapy is possible.
Dupilumab is authorized for AD in children starting from 6 months of age.
It is indicated from 6 months to 17 years as a 1st line systemic treatment for AD (moderate-to-severe for ages 6-17 and severe for ages 6 months to 5 years) after the failure of TCS.
In children, the dosage is as follows:
From 6 months to 5 years:
- Weight between 5kg and 15kg: 200mg every 4 weeks without a loading dose
- Weight between 15kg and 30kg: 300mg every 4 weeks without a loading dose
From 6 years to 11 years:
- Weight between 15kg and 60kg: loading dose of 300mg at Day 0 and Day 15, then 300mg every 4 weeks
- Weight ≥ 60kg: loading dose of 600mg, then 300mg every two weeks
From 12 to 17 years:
- If weight < 60kg: loading dose of 400mg, then 200mg every 2 weeks
- If weight ≥ 60kg: loading dose of 600mg, then 300mg every 2 weeks
➜ Lebrikizumab
Back to decision-making tree
Print
